期刊文献+

重组人脑利钠肽治疗老年患者急性心肌梗死泵衰竭的疗效 被引量:22

Therapeutic efficacy of recombinat human brain natriuretic peptide on elderly acute myocardial infarction with heart failure
原文传递
导出
摘要 目的探讨重组人脑利钠肽(rhBNP)治疗老年急性心肌梗死泵衰竭患者的效果。方法选取老年急性心肌梗死患者63例,分为治疗组和对照组,治疗组在常规治疗基础上静脉泵人重组人脑利钠肽,对照组在常规治疗基础上泵人硝酸甘油,均应用3~5d。观察两组患者治疗前后呼吸困难缓解比率、心率、血氧饱和度变化、左室射血分数(LVEF)、左室舒张末容积(LVDD)、血浆白介素6(IL-6)和超敏C反应蛋白(hsCRP)水平。结果治疗组总有效率79.3%(23/29),对照组总有效率64.7%(22/34)(P=0.017),治疗组呼吸困难症状缓解优于对照组(P〈0.05);心率、血氧饱和度、LVEF、hsCRP、IL-6治疗组治疗前分别为[(120±11)次/min、(78士6)%、(28±32)%、(25.78土2.44)mg/L、(40.74±5.43)μg/L],治疗后分别为[(89±9)次/min、(97±6)%、(43±20)%、(12.78±2.54)mg/L、(28.45±2.34)μg/L],治疗前后比较均P〈0.05;心率、血氧饱和度、LVEF、hsCRP、IL-6对照组治疗前分别为[(117±8)次/min、(80±8)%、(29±31)%、(21.44±1.33)mg/L、(41.87±5.46)μg/L3,治疗后分别为[(109士10)次/min、(34±18)%、(43±20)%、(17.63±1.62)mg/L、(36.56±3.02)μg/L3,治疗组在降低心率、hsCRP、IL-6及提高LVEF优于对照组(均P〈0.05)。结论重组人脑利钠肽治疗老年急性心肌梗死泵衰竭效果显著。 Objective To evaluate the clinical efficacy of recombinat human brain natriuretic peptide (rhBNP) in the treatment of acute myocardial infarction (AMI) with heart failure in aged patients. Methods Totally 63 elderly patients with AMI and heart failure were randomly divided into therapy (29 cases) and control (34 cases) groups. Besides routine treatment, the therapy group received rhBNP in continuous intravenous infusion, while control group was treated with nitroglycerin. Both drugs were administered for 3-5 days. The dyspnea remission rates after treatment were recorded. At the same time, heart rates and blood oxygen saturation, left ventricular ejection fraction (LVEF) and left ventricular end diastolic volume (LVDD), serum interleukin 6 (IL-6) and high sensitivity C reactive protein (hsCRP) were recorded before and after treatment. Results The total effective rate after the treatment was 79.3 %(23/29)in therapy group and 64.7% (22/34)in control group(P=0. 017). The dyspnea remission rate was better in therapy group than in control group (P(0.05). The heart rate, blood oxygen saturation, LVEF, hsCPR and IL-6 in therapy group were [(120+11)times/min,(78±6)%,(28±32)%,(25.78±2.44) mg/L,(40.74±5.43)μg/L] before treatment, and after treatment [ ( 89 ± 9) times/min, ( 97 ± 6) %, ( 43± 20) %, ( 12.78 ± 2.54) mg/L,(28.45±2.34) μg/L] (all P〈0. 05). The above indexes in control group were [(117+8) times/min, (80±8) %, (29±31) %, (21.44±1.33) rag/L, (41.87± 5.46) μg/L] before treatment , and after treatment(109±10) times/rain, (34±18) %, (43±20) %, (17.63±1.62) mg/L, (36.56± 3.02) vg/L]. The heart rate and the levels of IL-6 and hsCPR were reduced, blood oxygen saturation and LVEF were increased in therapy group than those in control group. Conclusions rhBNP is efficient in the treatment of elderly AMI with heart failure.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2012年第8期666-668,共3页 Chinese Journal of Geriatrics
关键词 脑利钠肽 急性心肌梗死 心力衰竭 Brain natriuretic peptide Myocardial infarction Heart failure
  • 相关文献

参考文献6

二级参考文献19

  • 1陈谦,潘伟民,叶红华.女性冠心病临床及冠脉造影特点分析[J].第二军医大学学报,2005,26(7):833-834. 被引量:10
  • 2谢洪智,朱文玲.重组人脑利钠肽和硝酸甘油治疗急性失代偿性心力衰竭疗效和安全性的随机、开放、平行对照的多中心临床研究[J].中华心血管病杂志,2006,34(3):222-226. 被引量:228
  • 3Jernberg T,Stridsberg M,Venge P,et al.N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation.J Am Coll Cardiol,2002,40:437-445.
  • 4Tsutamoto T,Wada A,Maeda K,et al.Attenuation of compensation of endogenous cardic natriuretic peptide system in chronic heart failure.Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.Circulation,1997,96:509-516.
  • 5Tycinska AM,Sobkowicz B,Mroczko B,et al.The value of apelin-36 and brain natriuretic peptide measurements in patients with first ST-elevation myocardial infarction.Clin Chim Acta,2010,411:2014-2018.
  • 6Caboral M,Mitchell J.B-type natriuretic peptide:a new tool in the armamentarium used to accurately diagnose heart failure.Prog Cardiovasc Nurs,2003,18:190-193.
  • 7杨波,夏勇,李东野.BNP与急性冠脉综合症患者左心功能相关性研究.徐州医学院,内科学(心血管病),2008.
  • 8Tasevska DG,Kennedy LM,Cline IA,et al.Gender differences in variables related to B-natriuretic peptide,left ventricular ejection fraction and mass,and peak oxygen consumption,in patients with heart failure.Int J Cardiol,2010,19:171-176.
  • 9Abraham WT,Lowes BD,Ferguson DA,et al.Systemic hemodynamic,neurohormonal,and renal excretory effects of a steady-state infusion of human brain natriuretic peptide in patients with decompensated chronic heart failure.J Card Fail,1998,4:37-44.
  • 10Mills RM,LeJemtel TH,Horton DP,et al.Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure:a randomized,double-blind,placebo-controlled clinical trial.Natrecor Study Group.J Am Coll Cardiol,1999,34:155-162.

共引文献244

同被引文献149

引证文献22

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部